Stago has listed articles and publications related to the current COVID-19 infection and focusing on thrombosis and haemostasis issues.
In this section, guidance and recommendations published by national and international societies are addressed.
This page is updated regularly once new information is published.
In a separate section, “Research Publications”, all published scientific content of interest is collected.
Sep 13, 2020. Gerotziafas GT, Catalano M, Colgan MP et al. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost. doi: 10.1055/s-0040-1715798.
The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease and presents an integral strategy for the management of patients with vascular disease or cardiovascular risk factors (VD-CVR) and COVID-19.
Oct. 12, 2020. American Society of Hematology (ASH) guidelines on the use of anticoagulation in patients with COVID-19
In June 2020, ASH formed a multidisciplinary, international panel to develop guidelines on the use of anticoagulants in patients with COVID-19. The panel prioritized questions about the use of anticoagulants in critically and acutely ill patients. On October 8, 2020, the panel agreed on the following recommendations described in this article. During October and November, these recommendations and a report on the guideline development process will undergo public review and ASH organizational review and approval, and will be submitted for publication in Blood Advances.
Oct. 12, 2020. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations
This paper compares existing guidelines issued by various learned societies on the management of coagulopathy and thrombosis in critically ill COVID-19 patients.
July 31, 2020. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.
Source: Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M.
Swiss Med Wkly. 2020 Jun 21;150:w20301. doi: 10.4414/smw.2020.20301. eCollection 2020 Jun 15.
This article consists in a systematic review of reported risk of venous thromboembolism associated with COVID-19 and a review of current guidelines on venous thromboembolism prophylaxis.
July 10, 2020. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring.
Source: Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, Godier A, Testa S, Levy JH, Albaladejo P, Gruel Y; GIHP and GFHT.
Version 2. Crit Care. 2020 Jun 19;24(1):364. doi: 10.1186/s13054-020-03000-7. PMID: 32560658
This paper includes joint GIHP-GFHT recommendations for prevention of thrombotic risk in patients with COVID-19 and haemostasis monitoring. Of note, this paper proposes an algorithm to determine the antithrombotique dose regimen according to patient’s status and ventilation procedure.
June 2, 2020. Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19
This guidance, developed by a multidisciplinary panel of experts in thrombosis and hemostasis, provides practical guidance for the management of VTE in hospitalized patients with suspected or confirmed COVID-19 infection. Objectives are to provide an approach to the diagnosis of VTE; address thromboprophylaxis strategies in ICU and non-ICU settings, including the duration of prophylaxis; and provide guidance on the treatment of VTE.
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
The JACC Journals and the ACC worked to provide COVID-19 clinical guidance for global cardiovascular clinicians. Herein, authors have reviewed the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
This publication is endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the North American Thrombosis Forum (NATF), the European Society of Vascular Medicine (ESVM), and the International Union of Angiology (IUA). Supported by the ESC Working Group on the Pulmonary Circulation and Right Ventricular Function
A Commentary, recently published by SC Cannegieter and FA Klok in RPTH, address the clinical guidance and research priorities of JACC guidance.
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.
The ISTH interim guidance recommends measuring D-dimer, prothrombin time and platelet count in all patients suspected of COVID-19 infection, in order to stratify risk of developing coagulopathy and to help in management.
An algorithm based on simple coagulation tests is proposed, including measurement of fibrinogen which may help to assess disseminated intravascular coagulation (DIC) in these patients. Finally, low molecular weight heparin (LMWH) treatment may be used in some COVID-19 patients.
Additionally to the guidance, two letters from same panel of authors provide more information and highlight specific topics:
Type and dose of heparin in COVID-19. Thachil J, Tang N, Gando S et al. J Throm Haemost 2020.
Laboratory haemostasis monitoring in COVID-19. Thachil J, Tang N, Gando S et al. J Throm Haemost 2020.
Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19
Source: Song JC, Wang G, Zhang W, et al. Military Medical Research (2020) 7:19. DOI: 10.1186/s40779-020-00247-7
This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.
Detailed recommendations for interactions with experimental COVID-19 therapies
Source: University of Liverpool.
In the course of COVID-19 infection management, a large number of patients are receiving off-label and compassionate use therapies such as chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, favipiravir, remdesivir, ribavirin, interferon beta. However, many of these experimental therapies may be subject to potential drug-drug interaction.
The University of Liverpool has provided detailed recommendation to prevent potential drug-drug interactions in patients receiving these experimental drugs.
A section dedicated to anticoagulant, antiplatelet and fibrinolytic therapies highlights caution about DOACs, VKAs and anti-PY12 agents. Of note, dose adjustments were suggested for patients receiving DOACs.
Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19.
This guidance from Thrombosis UK, authored by internationally recognized experts, helps with information to manage thrombotic risk, coagulopathy, and DIC in patients with COVID-19. This is a living guidance document that will be updated weekly.
The DIC score is of prognostic value in COVID-19 pneumonia.
The British Society on Haematology published guidance established using data published by haematologists from Wuhan, China. This document indicates abnormal coagulation parameters can be a useful predictor of prognosis in pneumonia due to COVID-19.
The above information is presented as scientific literature from the above publications, which, through their editorial boards consisting of independent reviewers with expertise in the subject of the article, have been made available electronically. Please see the original journal article for further information on how to access the content, as well as to review any relevant conflicts or biases for all authors, contributors, or editors associated with the journal or organization.
Some of the uses described of the manufacturer’s product have not been cleared by the FDA, or by your local agency. Please refer to https://www.stago.com/products-services/instructions-for-use/ for the current product labeling in alignment with the most recent FDA clearances for these products.